This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

With Tips From Pfizer, AbbVie Lands the Biggest Pharma Deal of the Year: StockTwits

NEW YORK (TheStreet) --Orchestrated by many of the deal wizards who led Pfizer's (PFE - Get Report) bidding for AstraZeneca (AZN - Get Report), AbbVie (ABBV - Get Report) has gained verbal confirmation from Shire PLC (SHPG - Get Report) to move forward with the largest non-U.S. drug merger of the year.

After five sequential bids, AbbVie's $53.7 billion offer for the Dublin-based company was approved late Monday. Led by Chief Executive Rick Gonzalez, the Chicago-based drugmaker will take the reins as long as it proves the deal logistics aren't just fancy words.

$ABBV accretive deal. hep c soon to be on the market. $70 stock. — Swingman24 (@Swingman24) Jul. 14 at 01:51 PM

Offering a 50.5% premium to Shire's market price before takeover speculation erupted four weeks ago, the deal is now only a 12% premium to Shire's closing price on Tuesday. AbbVie proposes to pay $44.71 in cash per share and swap each of the remaining Shire shares with 0.896 of an AbbVie share.

$ABBV getting destroyed. Overpaying for $shpg. $53 billion is way too much. Max pain coming — Ari Gold (@AriGold) Jul. 14 at 08:54 AM

$ABBV overpaying for $SHPG. This will not end good for Abbvie as debt load is simply astronomical on future revenues. — Ari Gold (@AriGold) Jul. 14 at 09:11 AM

With the premium in place, it is hard to believe the company isn't overpaying for the freedom to move its tax domicile, but there are a few less explicit factors adding to the deal as well. An analyst from British banking group Berenberg commented, "The company has to be of a certain size, because around 20% of the shareholders post-deal must be shareholders in the target company." The requirement ruled out quite a few of the options AbbVie could have executed on, smaller companies that cost much less, making Shire an even more lucrative target.

On the value front, according to an analyst from Bank of America Merrill Lynch, pending completion the deal will create $38 dollars per share in additional value to a combined company, which suggests AbbVie will be keeping upwards of 20% of that deal value to itself, discounting the purchase price significantly, and staying a lot of the complaining regarding the hefty premium.

The lessons taken from Pfizer extended further than just the deal team, AbbVie offered a 5% larger premium to Shire than Pfizer was willing to for AstraZenica, and also inserted "soft bids" to assure takeover discussion could be timeless. The latter may have been even more important, considering Pfizer's final bid deadlines expired on May 18 without any likely deal on the horizon. Indeed, the contrasting success and failure of AbbVie and Pfizer will be an important case for future deal talk, assuring open-ended discussions may supercede hard deadlines.

At the time of publication the author had no position in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ABBV $66.10 0.95%
AZN $67.68 -2.55%
PFE $34.11 -0.50%
SHPG $256.16 -1.52%
AAPL $129.62 -2.20%

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs